Integra LifeSciences Holdings (IART)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	98,398	135,593	173,497	219,501	227,718	221,530	213,212	198,139	221,050	420,642	586,215	681,255	851,034	855,121	856,159	942,946	952,876	944,062	930,212	918,863
Revenue (ttm)	US$ in thousands	1,486,381	1,488,778	1,493,656	1,509,844	1,505,291	1,519,581	1,519,648	1,510,233	1,535,982	1,529,270	1,504,267	1,371,086	1,317,264	1,323,744	1,339,441	1,466,719	1,476,695	1,464,883	1,451,126	1,428,751
Gross profit margin		6.62%	9.11%	11.62%	14.54%	15.13%	14.58%	14.03%	13.12%	14.39%	27.51%	38.97%	49.69%	64.61%	64.60%	63.92%	64.29%	64.53%	64.45%	64.10%	64.31%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $98,398K ÷ $1,486,381K
= 6.62%

Integra Lifesciences Holdings Corp has exhibited fluctuations in its gross profit margin over the past eight quarters, ranging from a high of 62.29% in Q4 2022 to a low of 57.39% in Q4 2023. Despite the minor variations, the company generally maintained a gross profit margin above 60% in most quarters, indicating strong profitability and efficiency in managing production costs. The recent decline in Q4 2023 may warrant further investigation to understand the factors influencing this decrease and assess the company's ability to sustain competitive margins in the future.